Introduction
============

Knee osteoarthritis (OA) is a common disease associated with tissue inflammation, physical disability and imbalanced homeostasis in the cartilage. Approximately 25% of people aged \>50 years experience knee pain, articular stiffness and decreased function due to knee OA ([@b1-etm-0-0-6101]). At present, various types of surgery are available for the treatment of knee OA. Arthroscopic surgery is a minimally invasive surgical procedure and is advocated as one treatment option for symptomatic relief. The procedure includes lavage, partial meniscectomy, limited synovectomy, excision of osteophytes, removal of loose bodies and adhesiolysis ([@b2-etm-0-0-6101],[@b3-etm-0-0-6101]). The curative effect is satisfactory; however, the long-term efficacy of arthroscopic surgery in the treatment of knee OA has remained a topic of controversy amongst clinicians ([@b4-etm-0-0-6101],[@b5-etm-0-0-6101]), since the surgery may remove cartilage fragments, mechanical irritations, inflammatory cells and other factors from the joint, but cannot reverse or repair the knee OA. Therefore, numerous investigators have sought solutions combining arthroscopic surgery and viscosupplementation, including steroids and hyaluronan (HA), to improve outcomes of knee OA ([@b6-etm-0-0-6101]--[@b10-etm-0-0-6101]). However, studies have suggested that the use of viscosupplementation to repair damaged articular cartilage has limited efficacy after arthroscopic surgery.

In the past decade, there has been an increasing interest in the use of ozone injection for the treatment of knee OA. Ozone is a soluble gas with high oxidative activity, and exerts an anti-nociceptive effect through several mechanisms ([@b11-etm-0-0-6101]). Several studies and clinical experiments have demonstrated that ozone therapy has positive effects in terms of reducing pain and inflammation, improving function and benefiting the trophism of bone and cartilage, increasing vascularization, and increasing repair of the articular and subchondral bone ([@b12-etm-0-0-6101]--[@b14-etm-0-0-6101]). Intra-articular ozone injections are an effective and low-cost procedure to control pain in knee OA. Based on this previous work, the aim of the present study was to investigate whether OA injections exert a beneficial effect on OA of the knee after arthroscopic surgery.

Materials and methods
=====================

### Participants

This study was approved by the Ethics Committee of the Sixth Affiliated Hospital of Guangzhou Medical University and was performed in accordance with the provisions of the World Medical Association\'s Declaration of Helsinki 1995 (revised in Tokyo, 2004). Due to the retrospective nature of the study, the Ethics Committee of the Sixth Affiliated Hospital of Guangzhou Medical University waived the requirement for study participants to provide informed consent ([@b15-etm-0-0-6101]).

The inclusion criteria were as follows: i) Patients with knee OA (Kellgren-Lawrence Grade II or III) ([@b16-etm-0-0-6101]) with pain ≥4 on the visual analogue scale (VAS) ([@b17-etm-0-0-6101]); ii) patients aged 60--80 years; iii) patients for whom any other conservative treatments had failed (non-anti-inflammatory steroidal drugs, rehabilitation or physical therapy); and iv) patients with stable knees without malalignment.

The exclusion criteria were as follows: i) Patients with severe OA or aged \<60 or \>80 years; ii) patients with any systemic, mental or neurological deficiency; iii) patients in whom any invasive procedure had been applied to the knee or any intra-articular injection had been administered prior to the treatment; and iv) patients with any formal contraindication to ozone therapy (thrombocytopenia, angiotensin-converting enzyme inhibitor treatment, favism, hyperthyroidism, serious cardiovascular instability or ozone) or a history of previous ozone therapy.

The participants of the present study were selected from a total of 110 patients who had undergone arthroscopic surgery at the Sixth Affiliated Hospital of Guangzhou Medical University (Qingyuan, China) between March 2011 and May 2014 and who were retrospectively evaluated. Among them, 90 patients had been diagnosed with mild-to-moderate or moderate knee OA (Kellgren-Lawrence Grade II or III) and met the enrolment criteria of the study. Following arthroscopic surgery, the patients were divided into two groups according to the type of treatment administered. In the ozone group, patients received 20 ml of 20 µg/ml ozone as intra-articular injections after arthroscopic surgery, while another group who did not receive any intra-articular ozone injection served as a control group. The intra-articular ozone injections were performed once per week for 4 consecutive weeks, starting 2 weeks after surgery. The mean duration of follow-up was 13.7 months and the minimum follow-up duration was 12 months. In the ozone group, 6 patients were lost to follow-up and 4 cases were lost to follow-up in the control group. At the final follow-up, there were 42 patients in the ozone group and 38 in the control group. All arthroscopic surgeries and injections were performed by the same experienced physicians. Data on endpoints were collected prior to arthroscopic surgery and at 6 weeks and 3, 6 and 12 months after arthroscopic surgery. Demographic data and all post-operative outcome data were obtained from patient records ([Fig. 1](#f1-etm-0-0-6101){ref-type="fig"}).

### Arthroscopic surgical procedure

The standard arthroscopic debridement was performed under spinal or general anesthesia. The procedure in these patients included lavage of the joint with varying amounts of serum saline solution, and debridement of roughened surfaces with removal of loose debris. Meniscal tears were often resected and only loose unstable fragments were repaired, while carefully preserving as much meniscal tissue as possible. Loose bodies were removed as required. According to the protocol specifications, all patients received the same analgesic and exercise program after surgery. Celecoxib (200 mg) was administered orally as an analgesic supplement from postoperative 3 h and was repeated every 8 h until 2 days post-operation if the recorded VAS score was ≥4. The total celecoxib consumption after the operation was also recorded.

### Intra-articular injection procedure

The patient was placed in a supine position with the knee in an extended position. The knee to be punctured was subjected to an anti-sepsis procedure with iodine. After the patella had been located, its medial margin was pressed to subluxation in the lateral margin to increase the articular rim as much as possible. A 22-gauge needle was inserted along the superlateral margin of the patella into the suprapatellar pouch without ultrasound or other imaging guidance. Physicians ensured that the needle was not inside a blood vessel by aspirating the syringe. The ozone generator (Herrmann, Germany) was set to produce ozone (O~3~) from O~2~ at a concentration of 20 µg/ml. A 20-ml syringe was connected to the exit of the generator and 20 ml of the produced gas was drawn into the syringe. Before the injection of gas ([@b18-etm-0-0-6101]), 2 ml 1% lidocaine was injected into the knee. Lidocaine was administered to reduce the burning pain felt in the knee during gas injection, which lasted several minutes.

### Outcome measures

The efficacy of the treatment was evaluated using the VAS ([@b17-etm-0-0-6101]), Lequesne index ([@b19-etm-0-0-6101]), and Western Ontario and McMaster University Osteoarthritis Index (WOMAC) questionnaires ([@b20-etm-0-0-6101]). In the VAS, the proband selects a whole number on a scale of 0--10, with 10 representing severe pain and 0 representing the absence of pain. The Lequesne index consists of 10 specific questions, including 5 items associated with pain or discomfort, 1 item associated with the maximum distance walked and 4 items associated with daily life activities. The score ranges from 0 to 24 points. The WOMAC scale consists of 24 questions that evaluate pain, stiffness and physical function during daily life activities, and each question has five response choices (none, mild, moderate, severe and extreme); the subtotal scores for pain (5 items), stiffness (2 items) and physical function (17 items) range from 0--20, 0--8 and 0--68, respectively, and the sum of all the points generates a value between 0 and 96 inclusive. Higher values indicate a worse patient condition. At the 12-month follow-up, the patient\'s overall impression of the treatment outcome was measured by a clinical global impression (CGI), including a 5-point ordinal scale (1, excellent; 2, good; 3, satisfactory; 4, unchanged; 5, worse).

### Statistical analysis

Statistical analyses were performed using the SPSS version 19.0 software package (IBM Corp., Armonk, NY, USA). Values are expressed as the mean ± standard deviation or sample proportions unless specified otherwise. To assess the normality of the data distributions, the data were compared using a Kolmogorov-Smirnov test. Quantitative data were compared between the two groups using an independent-samples t-test. The Chi-square test was used to assess the differences between the two groups in terms of qualitative data. To compare quantitative variables within each group prior to and after treatment, one-way analysis of variance with the LSD post hoc test was used. P\<0.05 was considered to indicate a statistically significant difference.

Results
=======

### Demographic characteristics of the patients

A total of 80 patients (mean age, 71.5 years; age range, 60--80 years) with symptomatic knee OA (Kellgren-Lawrence grade II or III), comprising 42 patients in the ozone group and 38 in the control group, were enrolled in the present study. The two groups were comparable in terms of baseline demographics and disease profile, and there were no statistically significant differences between the groups ([Table I](#tI-etm-0-0-6101){ref-type="table"}). After ozone injection, 5 patients in the ozone group experienced a mild pain accompanied by erythema; the pain disappeared within a few minutes.

### VAS, Lequesne index and WOMAC scores

Although the two groups had comparable baseline values, the VAS scores, Lequesne index scores, and the WOMAC-pain, WOMAC-stiffness, WOMAC-function and total WOMAC scores were significantly better in the ozone group than those in the control group at all post-operative follow-up time-points (P\<0.05; [Table II](#tII-etm-0-0-6101){ref-type="table"}; [Figs. 2](#f2-etm-0-0-6101){ref-type="fig"}--[4](#f4-etm-0-0-6101){ref-type="fig"}). The lower pain observed in the ozone group in the short term may be due to injection of Lidocaine into the joint during ozone administration. Of note, those differences were maintained even at 1 year post surgery. With regard to pain intensity, it was observed that the VAS scores significantly decreased from 7.52 prior to treatment to 5.17 at the 12-month follow-up in the ozone group, whereas in the control group, the VAS scores decreased from 7.66 to 6.56 ([Table II](#tII-etm-0-0-6101){ref-type="table"}; [Fig. 2](#f2-etm-0-0-6101){ref-type="fig"}). The Lequesne Index improved from 15.07 to 8.74 in the ozone group and from 14.26 to 10.08 in the control group at the 12-month follow-up ([Table II](#tII-etm-0-0-6101){ref-type="table"}; [Fig. 3](#f3-etm-0-0-6101){ref-type="fig"}). Furthermore, the WOMAC-pain, WOMAC-stiffness and WOMAC-function scores for the ozone group were significantly decreased from 12.36 to 6.71, 2.95 to 2.14 and 55.12 to 32.76, respectively. In the control group, the same scores decreased from 15.9 to 4.4, 3.32 to 2.68 and 57.45 to 37.87, respectively. The total WOMAC score decreased from 70.43 to 41.19 in the ozone group, and from 73.68 to 58.84 in the control group at the 12-month follow-up ([Table II](#tII-etm-0-0-6101){ref-type="table"}; [Fig. 4](#f4-etm-0-0-6101){ref-type="fig"}). No significant difference in the WOMAC-stiffness score was observed after surgery at the 6 and 12-month follow-up assessments compared with pretreatment in the control group ([Table II](#tII-etm-0-0-6101){ref-type="table"}).

### CGI scores

At the end of the follow-up of at least 12 months, based on the CGI, the treatment outcome was rated as excellent in 10 (23.8%), good in 17 (40.5%), satisfactory in 8 (19.0%), unchanged in 4 (9.5%) and worse in 3 (7.1%) patients in the ozone group. In the control group, the treatment outcome was rated as excellent in 5 (13.2%), good in 12 (31.6%), satisfactory in 10 (26.3%), unchanged in 7 (18.4%) and worse in 4 (10.5%) patients ([Fig. 5](#f5-etm-0-0-6101){ref-type="fig"}). Analysis of the physician\'s CGI scores at the 12-month follow-up indicated that a significantly higher number of patients in the ozone group had been assigned better CGI grades (excellent and good) compared with that in the control group (P\<0.05).

Discussion
==========

Knee OA is a degenerative disease that leads to painful joints, articular stiffness and decreased function. At present, no cure is available for knee OA, and the major objectives of treatment are the relief of symptoms, including pain, stiffness and swelling, improvement of function and limitation of joint damage leading to the destruction of the joint. The pathophysiology of knee OA is complex, and is characterized by the wearing of the articular cartilage with subsequent damage to the bones and increased matrix degradation. Most orthopedic surgeons include arthroscopic surgery as a treatment modality for patients with mild or moderate knee OA. Arthroscopic surgery for knee OA may delay joint degeneration to maintain moderate activity and allow for future reconstruction, particularly for patients with mild to moderate OA ([@b21-etm-0-0-6101],[@b22-etm-0-0-6101]). However, the treatment cannot reverse or stop the pathological process of OA or prevent its continuous development. Therefore, its long-term effects are less than ideal. In the present study, it was also demonstrated that the efficacy of arthroscopic treatment for patients with knee OA of Kellgren-Lawrence Grade II or III had no obvious effect in joints stiffness after 6 months of follow-up in the control group. Treatment approaches combining arthroscopic surgery with viscosupplementation have been trialed to improve the outcomes of knee OA. For instance, treatment combining arthroscopic surgery and hyaluronic acid has been widely used. Hempfling ([@b8-etm-0-0-6101]) reported that the post-arthroscopic instillation of 0.5% sodium hyaluronate into the joint is a suitable method for achieving long-term stabilization of the treatment outcome. Mathies ([@b7-etm-0-0-6101]) performed a study examining the outcomes of the use of 0.5% sodium hyaluronate immediately after arthroscopic surgery. This study indicated that the use of 0.5% sodium hyaluronate may be of benefit in reducing post-operative pain and swelling. In addition, Huskin *et al* ([@b23-etm-0-0-6101]) reported that viscosupplementation with hylan G-F 20 had a favorable risk-benefit profile in patients with symptomatic knee OA after arthroscopic meniscectomy and/or debridement of the knee in a patient with chondral disease.

Although ozone has been widely used for the treatment of orthopedic diseases, at present there is no unanimous protocol for ozone treatment in knee OA ([@b12-etm-0-0-6101],[@b14-etm-0-0-6101],[@b24-etm-0-0-6101]). It is a gas that is highly soluble in biological fluids, where atomic oxygen acts as a highly reactive species. After injection into a joint capsule, ozone is able to reduce inflammation, improve function and benefit the trophism, vascularization and repair of articular and subchondral bone. The biological mechanism of action of ozone therapy for knee OA is thought to be based on the biological effects elicited by ozone, including reactive oxygen species (ROS) and lipid oxidation products (LOPs) ([@b12-etm-0-0-6101]--[@b14-etm-0-0-6101]). It is considered that ROS and LOPs may inhibit the release of proteolytic enzymes or proinflammatory cytokines and stimulate the proliferation of fibroblasts and chondrocytes with increased synthesis of the matrix and articular cartilage ([@b25-etm-0-0-6101]). A randomized controlled trial comparing intra-articular injection of platelet-rich plasma, hyaluronic acid and ozone into the knee of OA patients indicated comparable effects on pain reduction among the three approaches after 1 month of treatment ([@b26-etm-0-0-6101]). Hashemi *et al* ([@b18-etm-0-0-6101]) reported that there was no significant difference in VAS and WOMAC scores between intra-articular dextrose and ozone treatment in patients with mild to moderate knee OA in the short term. Recently, Chansoria *et al* ([@b27-etm-0-0-6101]) indicated that in a randomized controlled trial, intra-articular injection of a combination of ozone and steroids in patients with primary knee OA resulted in a better outcome in terms of pain relief and functional improvements than that achieved with ozone alone. Several studies have indicated that intra-articular ozone injection for knee OA is a safe and effective treatment with a low risk of complications. In a single-blinded, controlled study comprising 84 patients, Invernizzi *et al* ([@b28-etm-0-0-6101]) demonstrated that in terms of safety, intra-articular ozone treatment is comparable to intra-articular sodium hyaluronate in chronic knee OA. In the present study, no serious complications occurred in the ozone treatment group. Only 5 patients felt a mild pain after the injection, which disappeared within a few minutes. This side effect was also reported by Lopes de Jesus *et al* ([@b29-etm-0-0-6101]).

The present study revealed that ozone treatment reduced pain, as measured by the VAS. It also improved the quality of life measured by the Lequesne Index score and total WOMAC score in the ozone group. These significant changes demonstrate the effectiveness of ozone therapy in reducing pain, and improving function and quality of life of these patients post-surgery. The positive results of intra-articular ozone injection for knee OA are further supported the results of Lopes de Jesus *et al* ([@b29-etm-0-0-6101]). Another recent study by Fernández-Cuadros *et al* ([@b30-etm-0-0-6101]) indicated that ozone treatment decreases the VAS, as well as the WOMAC-pain, WOMAC-stiffness and WOMAC-function scores in patients with knee OA. The present study also indicated that the ozone group had a significantly greater improvement in pain and function than the control group, according to the VAS, Lequesne index and WOMAC function scores. Based on the CGI score at the 12-month follow-up, 64.3% of the patients obtained excellent or good results in the ozone group. By contrast, only 42.1% of the patients obtained excellent or good results in the control group. The reason for the favorable long-term effects in the ozone group may be that ozone promotes better vascularization in bones and cartilage, and accelerating anabolism and recovery in osteoarticular diseases ([@b12-etm-0-0-6101]). However, the exact mechanism of action of ozone therapy in knee OA has remained to be fully elucidated, and further studies are required to confirm the results and the long-term outcome.

The present study had several limitations. First, it was limited by the small sample size, and lidocaine was not injected into the knee in the control group, which may have affected the results. It will be necessary to expand the sample size and perform rigorous prospective studies in the future. Furthermore, the present study only recruited patients with Kellgren-Lawrence grade II or III OA, so the results are difficult to generalize to all OA populations that have different degrees of radiographically evident severity. In addition, the present study only investigated the clinical symptomatic changes, and no imaging features of knee OA were studied.

In conclusion, the results of the present study demonstrated the efficacy of intra-articular ozone injections after arthroscopic surgery in relieving pain and improving physical function in knee OA of Kellgren-Lawrence grade II or III. However, the present results should be looked at with caution and require further validation in larger cohorts.
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###### 

Comparison of demographic data as well as VAS, Lequesne and WOMAC scores at baseline between the Ozone and Control groups.

  Parameter                                                          Ozone group (n=42)   Control group (n=38)   P-value
  ------------------------------------------------------------------ -------------------- ---------------------- ---------
  Age^[a](#tfn1-etm-0-0-6101){ref-type="table-fn"}^ (± SD)           68.83±5.56           69.63±4.96             0.502
    Median (range)                                                   69 (60--79)          71 (60--77)            
  Sex^[b](#tfn2-etm-0-0-6101){ref-type="table-fn"}^                                                              0.408
    Male                                                             17 (40.5)            12 (31.6)              
    Female                                                           25 (59.5)            26 (68.4)              
  Knee^[b](#tfn2-etm-0-0-6101){ref-type="table-fn"}^                                                             0.888
    Right                                                            27 (64.3)            25 (65.8)              
    Left                                                             15 (35.7)            13 (34.2)              
  Knee OA grade^[b](#tfn2-etm-0-0-6101){ref-type="table-fn"}^                                                    0.866
    Grade II                                                         24 (57.1)            21 (55.3)              
    Grade III                                                        18 (42.9)            17 (44.7)              
  VAS (initial)^[a](#tfn1-etm-0-0-6101){ref-type="table-fn"}^        7.52±1.57            7.66±1.32              0.682
  Lequesne (initial)^[a](#tfn1-etm-0-0-6101){ref-type="table-fn"}^   15.07±3.82           14.26±2.64             0.280
  WOMAC (initial)^[a](#tfn1-etm-0-0-6101){ref-type="table-fn"}^                                                  
    Pain                                                             12.36±2.79           13.55±3.45             0.091
    Stiffness                                                        2.95±1.75            3.32±2.04              0.394
    Physical function                                                55.12±6.99           57.45±6.16             0.120
    Total                                                            70.43±8.37           73.68±10.07            0.119

Independent-samples t-test

Pearson\'s Chi-square test. Values are expressed as n (%) or the mean ± standard deviation. WOMAC, Western Ontario and McMaster Universities OA Index; VAS, Visual Analogue Scale; OA, osteoarthritis.

###### 

VAS, Lequesne and WOMAC scores in the Ozone and Control groups at Baseline, at 6 weeks and at 3, 6 and 12 months after treatment.

                                                                                      WOMAC                                 
  --------------------------------------------------------- ----------- ------------- ------------ ----------- ------------ -------------
  Baseline                                                                                                                  
    Ozone group                                             7.52±1.57   15.07±3.82    12.36±2.79   2.95±1.75   55.12±6.99   70.43±8.37
    Control group                                           7.66±1.32   14.26±2.64    13.55±3.45   3.32±2.04   57.45±6.16   73.68±10.07
    P-value^[a](#tfn3-etm-0-0-6101){ref-type="table-fn"}^   0.682       0.280         0.091        0.394       0.120        0.119
  6 weeks                                                                                                                   
    Ozone group                                             3.69±1.14   5.86±2.40     4.90±2.25    1.67±1.12   28.55±5.00   35.12±6.23
    Control group                                           4.53±1.67   7.89±2.71     6.97±2.45    2.42±1.31   33.84±6.26   43.24±7.08
    P-value^[a](#tfn3-etm-0-0-6101){ref-type="table-fn"}^   0.010       0.001         \<0.001      0.008       \<0.001      \<0.001
    P-value^[b](#tfn4-etm-0-0-6101){ref-type="table-fn"}^   \<0.001     \<0.001       \<0.001      \<0.001     \<0.001      \<0.001
    P-value^[c](#tfn5-etm-0-0-6101){ref-type="table-fn"}^   \<0.001     \<0.001       \<0.001      0.014       \<0.001      \<0.001
  3 months                                                                                                                  
    Ozone group                                             3.81±1.57   6.02±2.05     5.69±2.32    2.00±1.12   28.98±7.35   36.67±8.11
    Control group                                           4.74±1.54   8.97±2.14     7.71±2.04    2.61±1.33   34.82±7.61   45.29±8.51
    P-value^[a](#tfn3-etm-0-0-6101){ref-type="table-fn"}^   0.009       0.046         \<0.001      0.034       \<0.001      \<0.001
    P-value^[b](#tfn4-etm-0-0-6101){ref-type="table-fn"}^   \<0.001     \<0.001       \<0.001      0.002       \<0.001      \<0.001
    P-value^[c](#tfn5-etm-0-0-6101){ref-type="table-fn"}^   \<0.001     \<0.001       \<0.001      0.049       \<0.001      \<0.001
  6 months                                                                                                                  
    Ozone group                                             4.71±1.42   7.19±2.24     5.83±1.81    2.25±1.47   29.95±6.67   38.02±7.66
    Control group                                           5.97±1.23   9.21±2.04     7.95±1.90    2.76±1.56   36.50±8.77   47.00±8.70
    P-value^[a](#tfn3-etm-0-0-6101){ref-type="table-fn"}^   \<0.001     0.037         \<0.001      0.042       \<0.001      \<0.001
    P-value^[b](#tfn4-etm-0-0-6101){ref-type="table-fn"}^   \<0.001     \<0.001       \<0.001      0.021       \<0.001      \<0.001
    P-value^[c](#tfn5-etm-0-0-6101){ref-type="table-fn"}^   \<0.001     \<0.001       \<0.001      0.126       \<0.001      \<0.001
  12 months                                                                                                                 
    Ozone group                                             5.17±1.43     8.74±2.89   6.71±2.38    2.33±1.37   32.76±6.64   41.19±7.64
    Control group                                           6.76±1.45   10.08±3.03    8.55±2.44    2.68±1.47   37.87±6.96   58.84±7.48
    P-value^[a](#tfn3-etm-0-0-6101){ref-type="table-fn"}^   \<0.001     0.046         \<0.001      0.047       0.001        \<0.001
    P-value^[b](#tfn4-etm-0-0-6101){ref-type="table-fn"}^   \<0.001     \<0.001       \<0.001      0.032       \<0.001      \<0.001
    P-value^[c](#tfn5-etm-0-0-6101){ref-type="table-fn"}^   0.008       \<0.001       \<0.001      0.080       \<0.001      \<0.001

Ozone vs. control groups at the same time points.

Ozone vs. baseline ozone group.

Ozone vs. the baseline control group. Values are expressed as the mean ± standard deviation. WOMAC, Western Ontario and McMaster Universities Osteoarthritis Index; VAS, Visual Analogue Scale.
